62 results
Page 3 of 4
8-K
vg6qd
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
EX-99.1
cpd9yoiideqv7ciotgg
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
EX-99.1
gbt4jxv1
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
j0cff1
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
p30w1st0j49
5 Nov 20
Sutro Biopharma Reports Third Quarter 2020 Financial Results
7:05am
8-K
EX-99.1
egmizej6k4f2z
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
424B5
1xvaeg6jlboz
12 May 20
Prospectus supplement for primary offering
5:02pm
8-K
EX-99.1
qbuccceoygr9
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
424B5
tfrrik7csn
11 May 20
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.1
gizna
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
29l3al45
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
thi 4d5j0fp
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
10-K
9bfg06k nb0
1 Apr 19
Annual report
12:00am
10-Q
fi49bn09lqy4f tx6w
14 Nov 18
Quarterly report
12:00am